Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374474 | 1.00 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL5360565 | 0.97 | TLR7 (0.77) | TLR7TLR8 | |
| SCHEMBL31006040 | 0.96 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL483645 | 0.96 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL5354224 | 0.95 | TLR7 (0.74) | TLR7TLR8 | |
| SCHEMBL29182349 | 0.95 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL5354054 | 0.93 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL5358579 | 0.92 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL5356930 | 0.91 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL5353504 | 0.91 | TLR7 (0.67) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | claimed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | claimed |
| US-11633494-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| EP-4148069-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2023-03-15 | — | — | EP | claimed |
| CN-115554406-A | anti-CD 20 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3763742-B1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-10-05 | — | — | EP | claimed |
| EP-4056594-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | Birdie Biopharmaceuticals Inc. (KY) | 2022-09-14 | — | — | EP | claimed |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-02-02 | — | — | US | claimed |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-12-29 | — | — | US | claimed |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-11-10 | — | — | US | claimed |
| EP-1541572-A1 | Thioether substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1341791-B1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2005-05-25 | — | — | EP | claimed |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-27 | — | — | US | claimed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | claimed |
| US-6664264-B2 | Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | claimed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | claimed |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633494-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885 |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | ERBB2, EGFR, TP53 | TLR7 362/4885TLR8 249/4885 |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR7 2007/4885TLR8 1153/4885 |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | CD47, TP53, CD74 | TLR7 198/4885TLR8 159/4885 |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | EGFR, ERBB2, ERBB3 | TLR7 634/4885TLR8 518/4885 |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.